<?xml version="1.0" encoding="UTF-8"?>
<p>This has been the case for a number of MA of iron oxide carbohydrate nanoparticles, but this history is in part also relevant for the discussion of tentative follow-on liposomal formulations or other categories within the general NBCD denomination umbrella. At present, glatiramoids are an even more difficult category for which we can generally state that there is no adequate preclinical comparison to establish clinical equivalence between a candidate “similar” formulation and the innovator/ original medicinal product (i.e., originator trademark Copaxone® from TEVA Pharmaceuticals Ltd). Even though the FDA dedicated extensive intramural and extramural research to the subject between 2013 and 2017 (
 <xref rid="B19" ref-type="bibr">19</xref>), follow-on products for Mylan in 2017 (and in Europe in 2018, in partnership with Synthon, almost in parallel with another European marketing authorization, through a partnership between Synthon and Alvogen) and also in 2018 for Sandoz (in partnership with Momenta Pharmaceuticals Inc.), were approved either with the use of placebo-controlled clinical data or in the GATE study against a COPAXONE arm (
 <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01489254" xmlns:xlink="http://www.w3.org/1999/xlink">https://clinicaltrials.gov/ct2/show/NCT01489254</ext-link>).
</p>
